Chengdu Kanghong Pharmaceutical Group Co., Ltd. announces its subsidiary, Chengdu Hongji Biotechnology Co., Ltd., has received a Notice of Approval for Drug Clinical Trial from the NMPA for KHN921 Injection. This gene therapy product targets hypertrophic cardiomyopathy caused by MYBPC3 mutations. The company also received a permit from the US FDA for KHN921 clinical trials in the US.
Summary generated by AI · Always verify with source document
Securities Code: 002773 Securities Abbreviation: Kanghong Pharmaceutical Announcement No.: 2026-043
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Announcement on Subsidiary Receiving Drug Clinical Trial Approval Notice
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
Sign in to read the full translation
Free accounts get 10 full releases per month. Pro subscribers get unlimited access.